NCT03353740View on ClinicalTrials.gov

Gallium-68 PSMA-11 Positron Emission Tomography (PET) Imaging in Patients With Biochemical Recurrence

PHASE3CompletedINTERVENTIONAL
Enrollment

346

Participants

Timeline

Start Date

September 20, 2017

Primary Completion Date

September 1, 2020

Study Completion Date

September 1, 2020

Conditions
Prostate Cancer
Interventions
DRUG

Ga-68 labeled PSMA-11 PET

Patients will be imaged using Ga-68 labeled PSMA-11 PET to determine if the presence of metastatic disease. Prostate Specific Membrane Antigen (PSMA) is a protein expressed on prostate cancer cells that can be imaged using small molecules that target this protocol.

Trial Locations (1)

94143

University of California, San Francisco, San Francisco

All Listed Sponsors
lead

Thomas Hope

OTHER

NCT03353740 - Gallium-68 PSMA-11 Positron Emission Tomography (PET) Imaging in Patients With Biochemical Recurrence | Biotech Hunter | Biotech Hunter